Marubeni Corporation has completed its investment in Phillips Pharma, strengthening its pharmaceutical strategic platform across 26 countries and regions. The move supports the development of a new antimalarial drug in Africa and facilitates the import and distribution of high-demand medicines across the continent. Combined with existing operations in Asia and the Middle East, Marubeni aims to improve access to pharmaceuticals, enhance cross-regional collaboration, and address gaps in healthcare infrastructure. The initiative aligns with its GC2027 strategy focused on scalable, high-value growth platforms.

Read the full article here for details on Marubeni’s global pharmaceutical strategy.